[Interferon α sensitizes human osteosarcoma cells to doxorubicin-induced apoptosis through p53-dependent pathway]

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Osteosarcoma is a primary bone malignancy with limited treatment options.
• Doxorubicin is a standard chemotherapeutic agent, but resistance can develop.
• Interferon-alpha (IFNα) has shown potential in cancer therapy.

Purpose of the Study:

• To investigate the synergistic effect of IFNα and doxorubicin on osteosarcoma cell apoptosis.
• To elucidate the molecular mechanisms underlying this interaction, focusing on the p53 pathway.
• To provide evidence for novel therapeutic strategies in osteosarcoma treatment.

Main Methods:

• Osteosarcoma cell lines (U2OS and MG63) were treated with IFNα and doxorubicin.
• Cytotoxicity assessed by MTT assay; apoptosis evaluated by flow cytometry and DNA fragmentation assays.
• Protein expression levels of key apoptosis-related genes (p53, Bax, Bcl-2, Mdm2, p21, caspase-3, PARP) analyzed via Western blot.
• p53 gene silencing performed using siRNA to confirm pathway involvement.

Main Results:

• IFNα significantly enhanced doxorubicin-induced cytotoxicity and apoptosis in p53-wildtype cells (U2OS), but not in p53-mutant cells (MG63).
• Combination treatment led to increased apoptotic morphological changes and DNA laddering.
• Doxorubicin and IFNα combination upregulated pro-apoptotic proteins (p53, Bax, Mdm2, p21) and downregulated anti-apoptotic protein Bcl-2.
• p53 silencing abrogated the enhanced cytotoxicity and apoptosis induced by the combination therapy.
• Activation of caspase-3 and PARP was significantly reduced upon p53 knockdown.

Conclusions:

• IFNα sensitizes human osteosarcoma cells to doxorubicin-induced apoptosis via a p53-dependent mechanism.
• The combination of IFNα with doxorubicin represents a potential therapeutic strategy for osteosarcoma.
• Targeting the p53 pathway could enhance the efficacy of chemotherapy in osteosarcoma treatment.